Pro-inflammatory cytokine ratios determine the clinical course of febrile neutropenia in children receiving chemotherapy

Mira Siegmund1†, Julia Pagel1,2,3†, Tasja Scholz1, Jan Rupp2,3, Christoph Härtel1 and Melchior Lauten1*†

Abstract

Background: Febrile neutropenia is a common and serious complication during treatment of childhood cancer. Empirical broad-spectrum antibiotics are usually administered until neutrophil cell count recovery. It was the aim of this study to investigate cytokine profiles as potential biomarkers using in-vitro sepsis models to differentiate between distinct clinical courses of febrile neutropenia (FN).

Methods: We conducted an observational study in FN episodes of pediatric oncology patients. Courses of neutropenia were defined as severe in case of proven bloodstream infection or clinical evidence of complicated infection. We collected blood samples at various time points from the onset of FN and stimulated ex vivo with lipopolysaccharide (LPS) and Staphylococcus epidermidis (SE) for 24 h. Twenty-seven cytokine levels were measured in the whole blood culture supernatants by a multiplex immunoassay system.

Results: Forty-seven FN episodes from 33 children were investigated. IL-8, IL-1β, and MCP-1 expression increased significantly over time. IL-8, MIP-1α, MIP-1β, MCP-1, and TNF-α showed significantly lower concentration in patients with a clinically severe course of the FN.

Conclusions: Distinct patterns of cytokine profiles seem to be able to determine infectious FN and to predict the severity of its clinical course. If these data can be verified in a multi-centre setting, this may finally lead to an individualized treatment strategy facilitating antibiotic stewardship in these patients.

Keywords: Febrile neutropenia, Childhood cancer, Cytokines, Biomarker

Background

Infections are a potentially life-threatening complication during childhood cancer treatment [1]. The empiric use of broad-spectrum antibiotics in patients with febrile neutropenia leads to a significant decrease in mortality and morbidity [2–5]. However, routine use of antibiotics may cause overtreatment of patients developing fever due to non-bacterial reasons, e.g., due to virus infection, mucosal damage, adrenal insufficiency, or chemotherapy itself [6]. In addition, the excessive use of broad-spectrum antibiotics is associated with the emergence of multidrug-resistant organisms, prolonged hospitalization, and structural changes of the gut microbiota [7–10]. Hence, there is an urgent need to evaluate biomarkers to guide individualized treatment strategies for patients at high risk for bacterial infection. Unfortunately, there is a paucity of markers allowing differentiation between infectious and non-infectious as well as bacterial and non-bacterial fever during neutropenia. Markers like C-reactive protein (CRP) and procalcitonin (PCT) are often considered to indicate infections and they are discussed as biomarkers in FN. Current studies suggest that PCT has better discriminatory ability than CRP [11, 12]. In addition, international risk models for the assessment of severity of infection are scarce [13–15] and neither the common infection parameter CRP nor the
highly sensitive PCT can reliably differentiate between neutropenic infections and chemotherapy-induced fever [16–18]. The role of cytokines in the onset of inflammation is well known. Nevertheless, their role for the diagnosis and course of bacterial infection has been controversially discussed [12, 16, 18–21].

Within the last years, multiplex arrays for small blood volumes have been established allowing simultaneous measurement of multiple cytokines [22]. In the setting of FN, multiplex arrays are suitable to quantify even small amounts of cytokines [23]. This study aimed at defining cytokine patterns being capable of distinguishing between severe and mild courses of febrile neutropenia in pediatric oncology patients within the first days of a febrile episode. We chose a sepsis ex-vivo model to achieve a clear discrimination between cytokines due to higher cytokine levels. In addition, an ex-vivo model allowed to reduce potential influence factors.

Methods
Study cohort
This single-center convenience sample study was conducted at the Department of Pediatric Oncology and Hematology at the University Hospital Schleswig-Holstein, Campus Lübeck. We used blood samples from patients receiving chemotherapy and developing episodes of febrile neutropenia between 2005 and 2012. Samples were collected at days 0, 1, 4, 7, 10, and 14 of the episodes. Day 0 was defined as the time directly before administration of the antibiotics. Samples of 53 patients were collected and samples of 33 children with 47 febrile episodes were included into our study. We excluded children younger than 18 months, children after allogeneic stem cell transplantation, children with progressive oncological disease or undergoing genetic syndrome, and patients with absent clinical data or blood samples (a minimum of three blood samples including day 1, 4, and day > 4 were required). We included a maximum of three episodes of each patient. The cohort was divided into two groups: hematological malignancies (acute lymphoblastic leukemia, acute myelogenous leukemia, Hodgkin’s lymphoma, Non-Hodgkin lymphoma, Langerhans cell histiocytosis) and solid malignancies (Ewing sarcoma, rhabdomyosarcoma, medulloblastoma, neuroendocrine ovarian carcinoma, desmoplastic small round cell tumor, low-grade astrocytoma). Patients with FN were analyzed in two risk groups according to clinical and microbiological findings: The first group (severe course group, SCG) included patients with proven bloodstream infection (detection of a causative pathogen in blood culture) and/or clinical evidence of complicated infection (escalation of antibiotic treatment, clinical deterioration after start of antibiotics). In the second group (mild course group, MCG) we analyzed samples from patients with FN, no clinical signs for sepsis, and normalization of body temperatures within 48 h after start of antibiotic treatment. Patient characteristics are shown in Table 1.

Clinical definitions
Fever was defined as a single body temperature (measured in ear or mouth) over 38.5 °C or two temperatures between 38.0 and 38.5 °C during a 1-h interval [24]. Neutropenia was defined as an absolute neutrophil count < 0.5 × 10⁹/L and/or leucocyte count < 1.0 × 10⁹/L with an expected decline.

Ex-vivo sepsis model
Heparinized full blood samples were suspended in Roswell Park Memorial Institute (RPMI) 1640 supplemented with 1% penicillin/streptomycin, 2 mM glutamine, 1 mM pyruvate, and nonessential amino acids (Seromed Biochrome, Berlin, Germany) at a concentration of 5 × 10⁹ leukocytes/L within 24 h after collection. The leucocyte count was measured at the time of sampling. Lipopolysaccharide (LPS, 30 ng/ml) or Staphylococcus epidermidis (SE; ATCC 12490; 1-10 colony forming unit/white blood cell) were added in order to stimulate cytokine production. These “stimulated samples” were transferred to cell culture flasks and incubated for 24 h with 37 °C in 5% CO₂. There was no red blood cell lysis performed. Afterwards, cells were separated and cell culture supernatant was stored at −80 °C. Incubated full blood samples without stimulation with LPS or SE (“unstimulated samples”) served as controls.

Cytokine assays
Cytokines from whole blood culture supernatants were measured using the cytometric bead array Bio-Plex Pro™ Human Cytokine 27-plex Assay and Bio-Plex® 200 system. All parameters were measured in ng/ml. We measured the following cytokines: IL-1β, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, PDGF-BB, MIP-1β, RANTES, TNF-α, and VEGF. We excluded cytokines, which were detected in less than two-thirds of the samples for final evaluation (IL-2, IL-5, IL-7, IL-12, IL-13, IL-15, and VEGF).

Statistics
Statistical analysis was performed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA). Patient characteristics were evaluated using descriptive statistical methods; variables were expressed as median and quartiles. Statistical differences were tested for paired data by using Wilcoxon-rank sum test and Friedman test. Results of the Friedman test were corrected by the Bonferroni correction. For unpaired data, we used the Mann-Whitney U test. In all tests, p-values < 0.05 were considered significant. All febrile neutropenia
episodes were treated as statistically independent, including repeated episodes in the same patients.

Results
Study cohort
In this study we included data of 47 febrile neutropenic episodes from 33 children receiving chemotherapy. In four episodes, there was a culture-proven infection (Pseudomonas paucimobilis, Proteus mirabilis, Klebsiella pneumoniae, Escherichia coli). In one of them, a Candida albicans infection was additionally found. No patient died during the febrile neutropenic episodes.

Detailed patient characteristics are shown in Table 1.

FN was treated with Tazobactam and Piperacillin in 93.62% of cases, 57.45% of these patients received Tobramycin in addition. Three patients were treated with Clindamycin and Gentamycin (2.13%), Clarithromycin (2.13%), or Ceftazidime (2.13%). In the SCG, escalation of antibiotic treatment was performed in 15 episodes and contained Meropenem (13.33%), Teicoplanin (6.67%), Meropenem plus Teicoplanin (20.0%), Vancomycin (20.0%), Vancomycin plus Meropenem (26.67%), and Metronidazole (6.67%). The median day of antibiotic escalation was day 4 of FN.

Cytokine expression over time
During the febrile episodes, there was a significant increase of cytokine concentration from day 1 to day 7, beginning at day 4 after LPS and/or SE stimulation. IL-8 expression significantly increased after LPS as well as after SE stimulation from day 1 to 7. IL-1β and MCP-1 expression only increased significantly after LPS stimulation (data not shown). There was no statistically significant difference between the power of LPS and SE to stimulate baseline cytokine expression. Every single expression value for all cytokines at each point of time is shown in the supplemental table 1.

Cytokine expression by risk stratification
Sixteen of the 47 febrile episodes were classified as severe courses (SCG) and 31 as mild courses (MCG). According to the relevance of clinical decision-making in daily hospital routine, we focused our analysis on days 1 and 4 after onset of fever. After both, SE and LPS stimulation, IL-8, MIP-1α, MIP-1β, MCP-1, and TNF-α showed significantly lower concentration in the SCG as compared to the MCG at both time points. One representative graph is depicted (Fig. 1). IL-1β and IL-1ra, however, only showed significantly lower expression levels in the SCG after SE stimulation and IL-6 only after LPS stimulation (data not shown).

There was a marked median leucopenia at day 1 of the episodes (0.5 × 10^9/L) and the main increase of median leucocyte count was seen between day 4 (0.85 × 10^9/L) and day 7 (2.4 × 10^9/L) (data not shown). As expected, median leucocyte counts in SCG increased later than in the MCG group (supplemental fig. 1).

Pro- and anti-inflammatory ratio
Dysbalances in pro- and anti-inflammatory cytokines can be found in sepsis patients. Therefore, we chose pro-inflammatory cytokines which act as key actors in

### Table 1 Patient characteristics

|                         | MCG² | SCG¹ |
|-------------------------|------|------|
| N                       | 31   | 16   |
| Median age at oncologic diagnosis in years (25th–75th quartile) | 8.65 (3.75–14.54) | – |
| Median Leucocytes x10⁹ day 1 (n = 20/14) (25th–75th quartile) | – | 0.54 (0.20–1.23) |
| Median Leucocytes x10⁹ day 4 (n = 25/15) (25th–75th quartile) | – | 1.40 (0.70–2.95) |
| Median Leucocytes x10⁹ day 7 (n = 18/13) (25th–75th quartile) | – | 3.95 (2.33–6.98) |
| Median CRP (mg/dl) day 4 (n = 10/7) (25th–75th quartile) | – | 23.60 (17.30–62.78) |
| Median CRP (mg/dl) day 7 (n = 6/5) (25th–75th quartile) | – | 13.70 (2.85–98.73) |
| Duration of Hospitalization in days (n = 24/9) (25th–75th quartile) | – | 7 (4.5–8) |

* Percent of total number. ** Percent of N = 31 (MCG) and N = 16 (SCG), respectively
¹Mild course group
²Severe course group
the regulation of infections (IL-1β plus IL-8) and divided the expression of the sum of both by anti-inflammatory cytokines (IL-1ra plus IL-10) to calculate a pro- and anti-inflammatory cytokine expression ratio. IL-1ra was chosen, since it acts as antagonist of IL-1β; IL-10 directly inhibits the inflammatory macrophages and thereby decreases the expression of pro-inflammatory cytokines. In addition, we calculated a second ratio only including the antagonists IL-1β and IL-1ra. We found that pro-inflammatory cytokines increased with time (Fig. 2a) and in parallel to leukocyte recovery (timeline of leukocyte recovery is shown in suppl. fig.). Predominance of pro-inflammatory cytokines was more pronounced in MCG than in SCG episodes (Fig. 2b). Same results were found in the ratio of four blood culture positive samples. There were no differences between both clinical risk groups concerning the IL-1β and IL-1ra ratio.

Cytokine expression stratified according to the type of malignant disease

SCG episodes were more frequent in the group of patients with hematological malignancies ($p = 0.028$, Table 1). All other strata were equally distributed. Neither LPS nor SE stimulated samples showed consistent differences between both groups. Only IFN-γ and MCP-1 show significant lower concentrations on more than one time

---

**Fig. 1** a MIP-1α expression after SE-stimulation and b MIP-1β expression after LPS-stimulation in pg/ml on days 0, 1, 4, 7, 10, and 14 during febrile neutropenia. Dark bars show expression levels in MCG patients, light bars show the same for SCG patients. Data are presented as box plots indicating median, 25%/75% quartiles and outliers with an interquartile range < 1.5. $P$ values are derived from Mann-Whitney $U$ test. $P$ values are just calculated for days 1 and 4.

**Fig. 2** Ratio of the pro- and anti-inflammatory cytokines (IL-8 + IL-1β) / (IL-1ra + IL-10) during febrile neutropenia (a). Part b shows the same ratio differentiated for patients with mild and severe clinical courses. Data are presented as box plots indicating median, 25%/75% quartiles and outliers with an interquartile range < 1.5. $P$ values are derived from Mann-Whitney $U$ test (b).
point (days 4 and 7) in patients with hematological dis-
edies after LPS stimulation (data not shown).

Discussion

Children with febrile neutropenia receive broad-
spectrum antibiotic treatment, although bacterial infec-
tion cannot be proven in the majority of episodes. Clin-
ical models to predict microbiologically defined infec-
tions have been established [15]; however, reliable biomarkers are still needed to differentiate patients with bacterial infection from those without infection.

The role of cytokines as infection markers is still sub-
ject to controversy even though they are well known for their crucial function in systemic inflammation. We in-
vestigated cytokine regulation during febrile neutropenia in childhood cancer patients and found that three cyto-
kines (IL-8, MCP-1, and IL-1β) increase during febrile neutropenia in an ex vivo sepsis model. In addition, we
found that pro-inflammatory cytokines exceed anti-
flammatory cytokines during leukocyte recovery and
that low IL-8, MIP-1α, MIP-1β, MCP-1, and TNF-α ex-
pression at the beginning of the febrile episodes seem to
hint at a more severe clinical course of the infection.

All cytokines indicating a severe clinical course are pro-
inflammatory cytokines, secreted by macrophages, fibroblasts, endothelial cells (MCP-1, IL-8), and T cells (TNF-α) [25, 26]. IL-8 activates neutrophils, basophils, and T cells and is one of the most prominently discussed cytokines in the context of febrile neutropenia [27, 28]. IL-8, together with other markers like PCT or IL-6, was found to be a reliable diagnostic marker for sepsis or bacteraemia [5, 11, 18, 29, 30] and to predict low-risk for bacterial infections [31]. However, IL-8 was also found not to be able to predict bacterial infections in febrile neutropenia in children [16, 32]. MIP-1α and MIP-1β activate monocytes, macrophages, and granulocytes but also induce production of IL-6, IL-1α, and TNF-α [31–33]. These cytokines are described in the context of sep-
sis as possible predictors of outcome; however, not in the context of FN [34, 35]. MCP-1 affects activation of monocytes, macrophages, and T cells and its expression is correlated with mortality in non-neutropenic sepsis patients and again, its role in context of febrile neutropenia in children has not yet been investigated [34, 36, 37]. TNF-α induces fever and shock. Its expression strongly depends on the regulation of IL-6 and IL-10 and, therefore, varies interindividually [38, 39]. Hence, its role as a marker for febrile neutropenia could not be determined yet [29, 40, 41].

Our study suggests that further prospective randomized trials are needed to evaluate cytokine profiles in ex vivo stimulation models as diagnostic markers. These markers could be an additional tool to support antibiotic steward-
ship predicting a severe course of febrile neutropenia. Due
to the high biological complexity of the inflammasome and its stimulation by chemotherapy-induced neutropenia, it would be plausible that cytokine regulation may not be diagnosed by measurement of a single cytokine alone but a number of different cytokines and the calculation of a pro-/anti-inflammatory cytokine ratio. In our study, we found an association of three cytokines and the develop-
ment of febrile neutropenia and, in addition, five potential candidates for the discrimination between a severe and a mild course of FN episodes. Other groups using unstimu-
lated samples found different results for cytokine regula-
tion [12, 31, 32, 42]. However, none of these groups had investigated high numbers of cytokines at the same time. In addition, none of these groups were able to calculate pro-/anti-inflammatory cytokine ratios to show that regu-
lation of single cytokines does not represent the entirety of cytokine regulation. We demonstrated that the com-
bined pro-/anti-inflammatory ratio is even more suitable to discriminate between severe and mild courses of FN than the antagonists IL-1ra and IL-1β.

As expected, leukocyte count increased during time of the febrile episode and this happened earlier in patients with MCG than in those with SCG. In daily routine, this parameter is not used as a predictive value for infection severity, but especially the neutrophil count is used as a parameter for termination of the antibiotic treatment [17]. Of interest, the increase of leukocyte recovery was accompanied with an increasing pro- and anti-
inflammatory cytokine ratio, whereas differential regula-
tion of single cytokines was observed earlier. This sug-
gests that (a) basic immune regulation is present even in neutropenic patients and (b) immune recovery precedes cellular recovery. One may interpret the pro- and anti-
inflammatory cytokine regulation as a hallmark of sys-
temic inflammation and it would be interesting to know, whether sustained inflammation is associated with long-
term comorbidity of the patients. However, this would be subject to future studies.

In this single-center observational study, we focused on the expression pattern of cytokines during febrile neutro-
penia in an ex vivo sepsis model. We chose this for its benefit of a minor dependence on limiting external (e.g.,
day time) and internal (patients intrinsic stress, regulation of hormones) potential influence factors. In addition, we aimed at achieving high levels of cytokines in order to fa-
cilitate the discrimination of cytokine patterns. The main
strength of our study is its contribution to define early biomarkers for discrimination of severe and mild clinical courses of FN, even though they need to be validated by prospective studies. Nevertheless, they might be able to support early clinical decision making. In the context of chronically sick children and the burden of increasing antibiotic resistances, shortening of antibiotic treatment of even a few days could already have a major impact.
However, this study has several limitations. First, the long incubation time needed for ex vivo stimulation as well as the complex protocol limits the use of our model for routine clinical diagnostics. By a recent multivariable meta-analysis including a variety of clinical and disease-related parameters as well as laboratory findings, Phillips et al. defined a model of determining an individual’s chance of microbiologically defined infection during febrile neutropenia episode [15]. This model finally consists of six components: malignancy type, temperature, clinical description of being severely unwell, hemoglobin level, total white blood cell count, and absolute monocyte count. This supports the findings of our study, showing that rather a combination of different inflammation/infection parameters might serve as a reliable model to discriminate bacterial infection from non-infectious episodes. A second limitation of our study might be the retrospective division of our cohort into the two groups of MCG and SCG, since this did not follow prospectively defined criteria. Antibiotic treatment of these groups was not identical, since escalation of antibiotics defined the SCG and antibiotic escalation itself might have influenced the expression of cytokines. In addition, supportive therapies such as Amphotericin B or Fluconazole were used more often in SCG than in MCG.

In conclusion, we propose that the regulation of cytokine levels as measured in a small panel of different cytokines could attribute to risk stratification of febrile neutropenia. Future prospective studies are needed to evaluate this distinct FN signature as a diagnostic biomarker and a prognostic tool for individualized strategies.

**Supplementary information**

**Supplementary information** accompanies this paper at https://doi.org/10.1186/s40348-020-00097-2.

**Additional file 1:** Supplemental Figure 1: Median leukocyte count (×10⁹/L) of MCG and SCG patients on days 0, 1, 4, 7, 10, and 14 of the episodes. Data are presented as box plots indicating median, 25%/75% quartiles and outliers with an interquartile range < 1.5. P values are derived from Mann-Whitney U test.

**Additional file 2:** Supplemental Table 1.

**Abbreviations**

CRP: C-reactive protein; FGF-β: Fibroblast growth factor-β; G-CSF: Granulocyte colony-stimulating factor; GM-CSF: Granulocyte-macrophage colony-stimulating factor; IFN-γ: Interferon-γ; IL: Interleukin; IP-10: Interferon gamma-induced protein-10; LPS: Lipopolysaccharide; MCG: Mild course group; MIP-1β: Macrophage inflammatory protein-1β; MCP-1: Monocyte chemotactic protein-1; PCT: Procalcitonin; PDGF-BB: Platelet-derived growth factor-BB; RANTES: Regulated upon activation normal T cell expressed and secreted; RPMI: Roswell Park Memorial Institute; SCG: Severe course group; SE: Staphylococcus epidermidis; TNF-α: Tumor necrosis factor-α; VEGF: Vascular endothelial growth factor

**Acknowledgements**

We thank all patients taking part in this study and the Lübeck-Hilfe für krebskranke Kinder e.V. and the Deutsche José Carreras Leukämie-Stiftung for generous financial support.

**Authors’ contributions**

TS included the patients into the study and acquired the samples. MS and JP performed the laboratory analyses, analyzed the clinical data, and did the statistical calculations. CH, JR, and ML designed the study and supervised data acquisition and analysis. MS and ML were responsible for writing the manuscript. All authors read and approved the final manuscript.

**Funding**

This study was supported by an unrestricted grant by the Lübeck-Hilfe für krebskranke Kinder e.V., Lübeck, Germany and the Deutsche José Carreras Leukämie-Stiftung, München, Germany.

**Availability of data and materials**

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Written informed consent was obtained from parents or legal representatives. The study was reviewed and approved by the Ethics Committee of the University of Lübeck (vote no. 12-006).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Pediatrics, Pediatric Hematology and Oncology, University of Lübeck, 23538 Lübeck, Germany. 2. Department of Infectious Diseases and Microbiology, University of Lübeck, Lübeck, Germany. 3. German Center for Infection Research (DZIF), partner site Hamburg-Lübeck-Borstel-Reims, Lübeck, Germany.

**Received:** 3 March 2020 **Accepted:** 21 May 2020

**Published online:** 09 June 2020

**References**

1. Freycon F, Trombért-Pavici B, Casagrande L, Bertrand Y, Plantaz D, Mared-Béard P (2008) Trends in treatment-related deaths (TRDs) in childhood cancer and leukemia over time: a follow-up of patients included in the childhood cancer registry of the Rhône-Alpes region in France (ARCERRA). Pediatr Blood Cancer 50(6):1213–1220

2. Ben Abraham R, Toren A, Ono N et al (2002) Predictors of outcome in the pediatric intensive care units of children with malignancies. J Pediatr Hematol Oncol 24(1):23–26

3. Laws H-J, Ammann RA, Lehrnbecher T (2005) Diagnostic procedures and management of fever in pediatric cancer patients. Klin Padiatr 217(Suppl 1): S9–S16

4. Macher E, Dubos F, Garnier N et al (2010) Predicting the risk of severe bacterial infection in children with chemotherapy-induced febrile neutropenia. Pediatr Blood Cancer 55(4):662–667

5. Strajewski GR, Nylen ES, Bell MJ et al (2005) Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitomin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatric Critical Care Med 6(2):129–135

6. Hakim H, Flynn PM, Knapp KM, Srivastava DK, Gaur AH (2009) Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 31(9):623

7. Ammann RA, Simon A, de Bont ES (2005) Low risk episodes of fever and neutropenia in pediatric oncology: is outpatient oral antibiotic therapy the new gold standard of care? Pediatr Blood Cancer 45(3):244–247

8. Raich DW, Holdsworth MT, Winter SS, Hutter JJ, Graham ML (2003) Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children. Value Health 6(2):158–166

9. te Poele EM, Tissing WJ, Kamps WA, de Bont ES (2009) Risk assessment in fever and neutropenia in children with cancer: what did we learn? Crit Rev Oncol Hematol 72(1):45–55
10. Bai L, Zhou P, Li D, Ju X (2017) Changes in the gastrointestinal microbiota of children with acute lymphoblastic leukaemia and its association with antibiotics in the short term. J Med Microbiol

11. Arif T, Phillips RS (2019) Updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment and management of fever during neutropenia in children with cancer. Pediatr Blood Cancer 66(10):e7887

12. Haesler GM, Carlisle F, Phillips RS (2013) An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer. Pediatr Infect Dis J 32(10):e390–e396

13. Lehmbacher T, Robinson P, Fisher B et al (2017) Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol 35(18):2082–2094

14. Miedema KG, Tissing WJ, Abbink FC et al (2016) The diagnostic value of cytokines in paediatric cancer patients—a national multicentre study. Eur J Cancer (Oxford, England: 1990) 53:16–24

15. Phillips RS, Sun L, Arman RA et al (2016) Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis. Br J Cancer 114(6): 623–630

16. Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U (2000) Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 111(4):1093–1102

17. Lehmbacher T, Groll AH, Aygemen P et al (2018) Empfehlungen zur Diagnostik und Therapie bei krebskranken Kindern mit Fieber und Neutropenie – Vergleich zweier aktueller Leitlinien. Klin Padiatr 230(03):115–121

18. Medeira KG, de Bont ES, Elenfen RF et al (2011) The diagnostic value of CRP, IL-8, PCT, and STEM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer 19(10):1599–1600

19. Lehmbacher T, Fleischhack G, Hanisch M et al (2004) Circulating levels and promoter polymorphisms of interleukins-6 and 8 in pediatric cancer patients with fever and neutropenia. Haematologica. 89(2):234–236

20. Oude Nijhuis CS, Daemen SM, Vellenga E et al (2002) Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. Crit Rev Oncol Hematol 44(4):163–174

21. Phillips RS, Wade R, Lehmbacher T, Stewart LA, Sutton AJ (2012) Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med 10:15

22. Tighe P, Negm O, Todd I, Fairclough L (2013) Utility, reliability and reproducibility of immunassay multiplex kits. Methods (San Diego, Calif) 61(1):23–29

23. Morgan E, Varro R, Sepulveda H et al (2004) Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol 110(3):252–266

24. Simon A. Diagnostik und Therapie bei Kindern mit onkologischer Grunderkrankung. Fieber und Granulozytopenie (mit febriler Neutropenie) außerhalb der allogenen Stammzelltransplantation. 2016;Deutsche Gesellschaft für pädiatrische Infektiologie (DGPI) und Gesellschaft pädiatrische Onkologie und Hämatologie (GPOH)/AWMF S2K Leitlinie, AWMF-Registernummer 048/014, finale Version 023.001.2016.

25. Mehta AK, Gracias DT, Croft M (2018) TNF activity and T cells. Cytokine. 101:14–18

26. Wilson CB (1991) The ontogeny of T lymphocyte maturation and function. J Pediatr 118(3):54–59

27. Allen TC, Kudowska A (2014) Interleukin 8 and acute lung injury. Arch Pathol Lab Med 138(2):266–269

28. Lanzotti VS, Póvoa P, Soares M, Silva JRL, Barbosa AP, Salluh JIF (2016) Use of biomarkers in pediatric sepsis: literature review. Rev Bras Ter Intensiva 28(4):472–482

29. de Araujo OR, Salomão R, Bruniait MKC et al (2017) Cytokine kinetics in febrile neutropenic children: insights on the usefulness as sepsis biomarkers, influence of Filgrastim, and behavior of the IL-23/IL-17 pathway. Mediat Inflamm 2013:165974

30. Engel A, Steinhach G, Kern P, Kern WV (1999) Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 31(2):185–189

31. Urbanoa V, Eldiukate A, Tamulieni I (2012) The diagnostic value of interleukin-6 and interleukin-8 for early prediction of bacteremia and sepsis in children with febrile neutropenia and cancer. J Pediatr Hematol Oncol 34(2):122–127

32. Hatzistilianou M, Rekliti A, Athanassiadou F, Catrini D (2010) Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukaemia. Inflamm Res 59(5):339–347

33. Kanama T, Strieter RM, Standford TJ, Burdick MD, Kunkel SL (1993) Expression and regulation of human neutrophil-derived macrophage inflammatory protein 1 alpha. J Exp Med 178(1):63–72

34. Chaudhry H, Zhou J, Zhong Y et al (2013) Role of cytokines as a double-edged sword in sepsis. In Vivo 27(6):669–684

35. O’Grady NP, Tropea M, Preas HL et al (1999) Detection of macrophage inflammatory protein (MIP-1a and MIP-2) during experimental endotoxemia and human sepsis. J Infect Dis 179(1):136–141

36. Bossink AW, Paemen L, Jansen PM, Hack CE, Thijs LG, Dammme JV (1995) Plasma levels of the chemokines monocyte chemotactic proteins-1 and -2 are elevated in human sepsis. Blood. 86(10):3841–3847

37. Deshmule SN, Kremlev S, Amini S, Savaya BE (2009) Monocyte chemotactant protein-1 (MCP-1): an overview. JIRC. 29(6):313–326

38. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA (1990) Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 75(1):40–47

39. Schulte W, Bernhagen J, Bucala R (2013) Cytokines in sepsis: potent immunoregulators and potential therapeutic targets—an updated view. Mediat Inflamm 2013:165974

40. Buyukberber N, Buyukberber S, Sevinc A, Camci C (2009) Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients. Med Oncol 26(1):55–61

41. Tang Y, Xiao C, Xie X et al (2011) Evaluation of TH1/TH2 cytokines as a rapid diagnostic tool for severe infection in paediatric haematology/oncology patients by the use of cytomtric bead array technology. Clin Microbiol Infect 17(1):1666–1673

42. Badurdeen S, Hodge G, Osborn M et al (2012) Elevated serum cytokine levels using cytometric bead array predicts culture-positive infections in childhood oncology patients with febrile neutropenia. J Pediatr Hematol Oncol 34(1):e36–e38

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.